The overall 10-year risk of BRC recurrence of patients with a HER2/neu positive tumor was 22%, varying between 28% among those with HR negative tumor and 20% among those with a HR positive tumor (p < 0.001, data not shown). The gene discussed is ERBB2; the disease is neoplasm.